Citius Pharmaceuticals

LYMPHIR is now commercially available and, according to management, is increasingly being adopted in hospitals and by insurers; 135 payers offer full coverage, including Medicare. In the first three quarters of fiscal 2024 the product generated $7.1 million in revenue with a gross margin of 77%, and the full 29-person sales team was recently deployed. Citius emphasizes a cost-conscious balance sheet with $17 million in cash, recent capital inflows, and a 71% stake in Citius Oncology, whose value it believes is not reflected in the parent’s valuation. » More on de.investing.com

Citius Pharmaceuticals has completed a registered direct placement with gross proceeds of approximately $5 million, selling 5,076,143 common shares or pre-funded warrants at $0.985 each. In parallel, warrants to purchase an additional 5,076,143 shares were issued in a private placement at an exercise price of $0.86; these are immediately exercisable and expire five years after the registration statement becomes effective. H.C. Wainwright & Co. acted as sole placement agent. Net proceeds are intended to support the launch of LYMPHIR, development initiatives for product candidates, and general corporate purposes; the stock is currently trading below the issue price. » More on de.investing.com

Citius Pharmaceuticals sold 5,076,143 common shares at $0.985 per share in a registered direct offering and simultaneously issued warrants for up to 5,076,143 shares with an exercise price of $0.86. The transaction is expected to generate approximately $5 million in gross proceeds before fees; closing is expected today. H.C. Wainwright acted as placement agent, and the proceeds are intended primarily for the commercial launch of LYMPHIR, as well as for product development and general corporate purposes. Analysts see a possible move into profitability in 2026 with an expected earnings per share of $1.62; the stock is currently trading around $0.93 and has recovered since the start of the year. » More on de.investing.com